相关实验视频
Updated: Jun 13, 2025

12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
34.5K
介白素16和25 (IL-17E) 和临床结果在COPD恶化的试点研究-A试点研究
Tomasz Karauda1, Joanna Miłkowska-Dymanowska1, Anna Kumor-Kisielewska1
1Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.
Journal of clinical medicine
|September 14, 2024
概括
这项研究发现,慢性阻塞性肺病 (ECOPD) 恶化的患者中,白内素-16 (IL-16) 的水平较低,白内素-25 (IL-25) 的水平较高. 较低的IL-16与增加的死亡率相关,表明其作为ECOPD结果的预测标记物的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 生物标志物 生物标志物
背景情况:
- 慢性阻塞性肺病 (ECOPD) 的恶化显著影响患者的健康,增加住院和死亡率.
- 了解ECOPD的预测因素对于疾病管理至关重要.
- 介质蛋白-16 (IL-16) 和介质蛋白-25 (IL-25) 在ECOPD中的作用尚不清楚.
研究的目的:
- 研究IL-16和IL-25作为ECOPD临床结果的潜在预测标记物的作用.
- 探索IL-16,IL-25和疾病严重程度,炎症标志物和COPD患者的存活率之间的关系.
主要方法:
- 对50名患有COPD的前吸烟者的前性分析 (22名ECOPD,28名稳定).
- 测量IL-16和IL-25的血清度.
- 对中性粒细胞与淋巴细胞比率 (NLR) 的相关性评估,绝对氨基细胞计数,FEV1,FVC和全因死亡率.
主要成果:
- 与稳定的COPD患者相比,ECOPD患者的IL-16和IL-25水平显著降低,较高.
- IL-16水平与NLR负相关,与FEV1和FVC正相关.
- 在生存分析中,较低的IL-16度与明显更高的全因死亡率有关.
结论:
- 在ECOPD中较低的IL-16水平可能反映了与Th1反应激活相关的反机制,与呼吸系统参数和生存相关.
- 在ECOPD中较高的IL-25,与异常相关性与乙素,表明复杂的调节和潜在的Th1/Th2不平衡.
- 建议在更大的队列中进一步验证以确认这些发现.
相关概念视频
T Cell Types and Functions
961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
COPD: Pathogenesis and Clinical Features
244
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
244
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188

